Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Mean Percent Change in Non-low-density Lipoprotein Cholesterol (Non-HDL-C)From Baseline to Final Visit

\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\] x 100

Time frame: Baseline to 12 Weeks

Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit

\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\] x 100

Time frame: Baseline to 12 Weeks

Mean Percent Change in Total Cholesterol From Baseline to Final Visit

\[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol\] x 100

Time frame: Baseline to 12 Weeks

Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit

\[(Week 12 Apo B minus baseline Apo B)/baseline Apo B\] x 100